Forvis Mazars Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Forvis Mazars Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$222K	Sell	446 -72	-14%	-$31.9K	﹤0.01%	416
2026 Q1	$231K	Buy	518 +16	+3%	+$7.46K	﹤0.01%	384
2025 Q4	$228K	Sell	502 -90	-15%	-$38.8K	﹤0.01%	386
2025 Q3	$232K	Sell	592 -1,008	-63%	-$421K	﹤0.01%	384
2025 Q2	$712K	Buy	1,600 +152	+10%	+$70K	0.02%	239
2025 Q1	$702K	Buy	+1,448	New	+$675K	0.02%	239
2020 Q4	–	Sell	-847	Closed	-$230K	–	361
2020 Q3	$230K	Buy	847 +35	+4%	+$9.66K	0.01%	294
2020 Q2	$236K	Buy	+812	New	+$220K	0.02%	278

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Forvis Mazars Wealth Advisors's VRTX Position: Q2 2026 in Review

Forvis Mazars Wealth Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, selling an estimated $31.9K and leaving 446 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #416.

Forvis Mazars Wealth Advisors first reported a position in VRTX in Q2 2020 and has held it in 8 quarters since. The position peaked at $712K in Q2 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Forvis Mazars Wealth Advisors held 446 shares of Vertex Pharmaceuticals worth $222K as of Q2 2026.
Forvis Mazars Wealth Advisors sold 72 Vertex Pharmaceuticals shares in Q2 2026, an estimated $31.9K.
Vertex Pharmaceuticals made up ﹤0.01% of Forvis Mazars Wealth Advisors's portfolio in Q2 2026, its #416 holding.
Forvis Mazars Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 8 quarters since.
Forvis Mazars Wealth Advisors's Vertex Pharmaceuticals position peaked at $712K in Q2 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Forvis Mazars Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.